Pomalidomide(pomalyst) 4MG cap
Ended Awarded Last action
- Contract number
- 36C24526N0540
- Awardee
-
Bristol-Myers Squibb Company UEI UFGKB2B71N12
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $16,422
Award facts
- Contract value 100% obligated
- $16,421.95 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Memphis, TN 38141, USA
Award details come from SAM.gov/FPDS.
About this award
Bristol-Myers Squibb Company has received a $16,421.95 firm fixed-price delivery order from Veterans Integrated Service Network 5 (VISN 5) for Pomalidomide (Pomalyst) 4mg capsules, with an ultimate completion date of April 29, 2026. This award is issued under Bristol-Myers Squibb's Federal Supply Schedule contract (ID: 36F79724D0101) for Pharmaceuticals and Drugs (FSS-61-IB) with the Department of Veterans Affairs, a master schedule contract with a substantial ceiling value of $12.28 billion extending through April 30, 2029. The contract contains no set-aside designations, reflecting Bristol-Myers Squibb's status as a large biopharmaceutical manufacturer. The place of performance is identified as Memphis, Tennessee, supporting the VA's mission to provide advanced pharmaceutical therapies to eligible veterans.
Pomalidomide is a specialized oncology pharmaceutical used in the treatment of multiple myeloma and related hematologic malignancies, consistent with Bristol-Myers Squibb's portfolio of cancer therapies supplied to the VA healthcare system. Since 2022, the Department of Veterans Affairs has issued more than fifty delivery orders to Bristol-Myers Squibb across multiple Veterans Integrated Service Networks, demonstrating sustained procurement demand for the company's oncology and immunotherapy products that represent current standards of care in cancer treatment. This delivery order reflects the VA's ongoing need for advanced pharmaceutical support across its integrated service networks to serve the veteran population.
Quick answers
Who was awarded contract 36C24526N0540?
36C24526N0540 was awarded to Bristol-Myers Squibb Company by Veterans Integrated Service Network 5 (Veterans Health Administration) on April 23, 2026.
How much is contract 36C24526N0540 worth?
The government has obligated $16,422 on 36C24526N0540.
Is contract 36C24526N0540 an order under another contract?
Yes. 36C24526N0540 is a BPA call under 36F79724D0101-36E79726A0010, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0540 competed?
The extent of competition for 36C24526N0540 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award